Immunocore Holdings plc Stockholders Equity

Quick Answer

Immunocore Holdings plc reported Stockholders Equity of $381.03 million for fiscal year 2025.

Immunocore Holdings plc Stockholders Equity — Annual History

Fiscal Year Stockholders Equity YoY Change
2025 $381.03M +5.6%
2024 $360.72M -2.2%
2023 $368.84M +8.8%
2022 $338.90M +45.0%
2021 $233.71M +203.9%
2020 $76.91M

Quarterly Stockholders Equity

Quarter Ending Stockholders Equity YoY QoQ
September 30, 2025 $396.56M +5.0% +2.1%
June 30, 2025 $388.48M +8.2% +2.6%
March 31, 2025 $378.48M +5.3% +4.9%
December 31, 2024 $360.72M -2.2% -4.5%
September 30, 2024 $377.83M +6.1% +5.2%
June 30, 2024 $359.14M +2.2% -0.1%
March 31, 2024 $359.53M +5.3% -2.5%
December 31, 2023 $368.84M +8.8% +3.6%
  • Immunocore Holdings plc showed an increase of +5.6% in Stockholders Equity compared to the prior fiscal year.
  • Over the 2020–2025 period, Immunocore Holdings plc’s stockholders equity has grown by 395.4% (from $76.91 million to $381.03 million).
  • The most recent figure is from Immunocore Holdings plc’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 25, 2026.
  • All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.

Last verified:

Leave a Comment